GB201507926D0 - Improved treatments using oligonucleotides - Google Patents

Improved treatments using oligonucleotides

Info

Publication number
GB201507926D0
GB201507926D0 GBGB1507926.2A GB201507926A GB201507926D0 GB 201507926 D0 GB201507926 D0 GB 201507926D0 GB 201507926 A GB201507926 A GB 201507926A GB 201507926 D0 GB201507926 D0 GB 201507926D0
Authority
GB
United Kingdom
Prior art keywords
oligonucleotides
improved treatments
treatments
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1507926.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProQR Therapeutics BV
Original Assignee
ProQR Therapeutics BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProQR Therapeutics BV filed Critical ProQR Therapeutics BV
Priority to GBGB1507926.2A priority Critical patent/GB201507926D0/en
Publication of GB201507926D0 publication Critical patent/GB201507926D0/en
Priority to PCT/EP2016/060344 priority patent/WO2016180784A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1507926.2A 2015-05-08 2015-05-08 Improved treatments using oligonucleotides Ceased GB201507926D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1507926.2A GB201507926D0 (en) 2015-05-08 2015-05-08 Improved treatments using oligonucleotides
PCT/EP2016/060344 WO2016180784A1 (en) 2015-05-08 2016-05-09 Improved treatments using oligonucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1507926.2A GB201507926D0 (en) 2015-05-08 2015-05-08 Improved treatments using oligonucleotides

Publications (1)

Publication Number Publication Date
GB201507926D0 true GB201507926D0 (en) 2015-06-24

Family

ID=53489357

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1507926.2A Ceased GB201507926D0 (en) 2015-05-08 2015-05-08 Improved treatments using oligonucleotides

Country Status (2)

Country Link
GB (1) GB201507926D0 (en)
WO (1) WO2016180784A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
NZ587547A (en) 2004-06-24 2012-09-28 Vertex Pharma Modulators of ATP-Binding Cassette Transporters
PL3219705T3 (en) 2005-12-28 2020-08-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NZ624460A (en) 2009-03-20 2015-12-24 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
IL265430B1 (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical compositions containing a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamode and uses thereof
KR20230136689A (en) 2016-03-14 2023-09-26 에프. 호프만-라 로슈 아게 Oligonucleotides for reduction of pd-l1 expression
CA3056432A1 (en) * 2017-03-19 2018-09-27 Suzhou Sirnaomics Biopharmaceuticals Co., Ltd. Gemcitabine derivatives for cancer therapy
MX2019013158A (en) * 2017-05-04 2020-02-07 Sanofi Sa Methods for treatment of alport syndrome.
MX2020009147A (en) * 2018-03-02 2020-09-28 Ionis Pharmaceuticals Inc Modulators of irf4 expression.
JP2021533198A (en) * 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. Muscle targeting complexes and their use
IL300287A (en) * 2020-07-31 2023-04-01 Ractigen Therapeutics Combinatory treatment of sma with sarna and mrna modulators
CA3235096A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US20010049436A1 (en) * 1998-04-01 2001-12-06 Wen-Qiang Zhou Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
WO2009061841A2 (en) * 2007-11-05 2009-05-14 Isis Pharmaceuticals, Inc. Modified polynucleotides as antidotes to antisense compounds
RS54944B1 (en) * 2012-07-12 2016-11-30 Proqr Therapeutics Ii Bv Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell

Also Published As

Publication number Publication date
WO2016180784A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
IL256634A (en) Therapeutic oligonucleotides
IL257091B (en) Targeted oligonucleotides
AU367336S (en) Hairbrush
HK1257273A1 (en) Combination comprising immunostimulatory oligonucleotides
GB201503408D0 (en) Oligonucleotides
GB201507926D0 (en) Improved treatments using oligonucleotides
PT3197456T (en) Cancer treatments
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
GB201504124D0 (en) Oligonucleotides
GB201511218D0 (en) Reservoir treatments
GB201519450D0 (en) Novel treatment
GB201412011D0 (en) Treatments
GB201508841D0 (en) Treatment
PL3329004T3 (en) Therapeutic oligonucleotides
SG11201700652PA (en) Modified antimir-138 oligonucleotides
GB201412976D0 (en) Hair treatments
GB201411027D0 (en) Treatment
GB201714330D0 (en) Oligonucleotides
GB201721384D0 (en) Surface Treatments
GB201503008D0 (en) Treatment
GB2555225B (en) Hydrocarbon-contamination treatment unit
GB201518349D0 (en) Treatment
GB201515739D0 (en) Treatment
GB201514008D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)